AN ACT to create and enact four new sections to chapter 26.1-27.1 of the North Dakota Century Code, relating to pharmacy benefits managers and a pharmacy benefit manager enforcement fund; to amend and reenact subsection 1 of section 26.1-01-07, sections 26.1-27.1-01, 26.1-27.1-02, 26.1-27.1-04, 26.1-27.1-06 and 26.1-27.1-07 of the North Dakota Century Code, relating to pharmacy benefits managers; to repeal section 26.1-27-01.1 and chapter 26.1-36.10 of the North Dakota Century Code, relating to pharmacy benefits managers and prescription drug costs; to provide a penalty; to provide an appropriation; to provide for a transfer; to provide an effective date; to provide an expiration date; and to declare an emergency.
House Bill No. 1584 aims to regulate pharmacy benefits managers (PBMs) in North Dakota by establishing a licensing framework and creating an enforcement fund. The bill amends existing statutes related to PBMs, introduces new definitions, and sets forth licensing requirements, including fees and penalties for non-compliance. It also mandates that PBMs disclose certain financial information to ensure transparency in their operations and the impact on drug pricing for consumers.
The bill significantly alters the regulatory landscape for pharmacy benefits managers in North Dakota by requiring them to obtain a license to operate, thus subjecting them to state oversight. It establishes penalties for violations of the law, including monetary fines and potential license revocation. The creation of the Pharmacy Benefit Manager Enforcement Fund will provide resources for the enforcement of these regulations and aims to enhance consumer protection regarding prescription drug costs.
The sentiment surrounding HB1584 appears to be largely positive, as evidenced by the overwhelming support in the House (92-0) and a strong majority in the Senate (42-5). The discussions indicate a consensus on the need for greater regulation of PBMs to protect consumers and ensure fair practices in the pharmaceutical industry.
Despite the general support for the bill, there are notable points of contention, particularly among some senators who expressed concerns about the potential impact of increased regulation on the operational flexibility of PBMs. Critics argue that overly stringent regulations could lead to higher costs for consumers and reduced access to medications. Proponents counter that the bill is necessary to increase transparency and accountability in the PBM industry.